Excellent
Fully Aligned
Patient Risk:
Low
Summary
The provided assessment and verdict align with the label’s Boxed Warning/Section 5.1 and Section 4 contraindications regarding thyroid C-cell tumors (including MTC) and contraindication in patients with personal/family history of MTC or MEN 2; it also correctly reflects that human relevance is unknown.
Category Scores
Accurate Statements
Supported: yes; the label states semaglutide causes thyroid C-cell tumors in rodents and that human relevance (including MTC) is unknown.
SECTION 5.1 Risk of Thyroid C-Cell Tumors; BOXED WARNING; SECTION 13.1
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2.
SECTION 4 Contraindications; SECTION 5.1; BOXED WARNING
The claim is consistent with labeling language: it does not affirm proven human causality and correctly reflects that human relevance is unknown while the contraindications are explicit.
SECTION 5.1 (human relevance not determined); BOXED WARNING; SECTION 4
Unsupported Statements
Contradictions
Important Omissions
No additional label counseling content (e.g., examples of thyroid tumor symptoms; statement about routine calcitonin/thyroid ultrasound monitoring being of uncertain value) is included in the specific claim verdict text, though it is mentioned in the user-provided label excerpt and not required to validate the stated claim.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The assessment accurately matches the label’s boxed warning/Section 5.1 and contraindications in Section 4 for patients with MTC or MEN 2, without introducing unsupported causal claims in humans.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement